Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (10) : 958-962     DOI: 10.3971/j.issn.1000-8578.2021.21.0316
|
Correlation Between cyclin G1 Expression and Efficacy of Radiotherapy on Primary Hepatocellular Carcinoma
XU Gang, BU Shanshan, WANG Xiushen, GE Hong
Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
Download: PDF(4676 KB)   ( 59 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the correlation between cyclin G1 expression and the efficacy of radiotherapy on HCC. Methods The expression of cyclin G1 in biopsy specimens of 68 patients who received radiotherapy was detected by immunochemistry. The correlation between cyclin G1 expression and clinicopathological characteristics was analyzed by chi-square test. The correlation between cyclin G1 expression and OS or PFS was evaluated by Kaplan-Meier analysis. Univariate and multivariate analyses were used for the relation between clinicopathological characteristics and OS or PFS. Results The expression of cyclin G1 was related to portal vein tumor embolus, clinical stage and alpha fetoprotein. Survival analysis showed that the OS and PFS of patients with low expression of cyclin G1 were significantly higher than those with high cyclin G1 expression (P<0.05). Multivariate analysis showed that cyclin G1 was an independent risk factor for DFS of patients with HCC. Conclusion High expression of cyclin G1 is an adverse prognostic factor for HCC patients who received radiotherapy.
Keywords cyclin G1      Hepatocellular carcinoma      Radiotherapy      Prognosis     
ZTFLH:  R735.7  
  R730.5  
Fund:Henan Science and Technology Department, Key R&D Promotion Project (No.192102310102)
Issue Date: 15 October 2021
 Cite this article:   
XU Gang,BU Shanshan,WANG Xiushen, et al. Correlation Between cyclin G1 Expression and Efficacy of Radiotherapy on Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 958-962.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0316
http://www.zlfzyj.com/EN/Y2021/V48/I10/958
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
XU Gang
BU Shanshan
WANG Xiushen
GE Hong
[1] Vogel A, Saborowski A. Current strategies for the treatment of
intermediate and advanced hepatocellular carcinoma[J]. Cancer

Treat Rev, 2020, 82: 101946.

[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet,
2018, 391(10127): 1301-1314.
[3] 马中山, 马云玲, 冯丽. 放疗在原发性肝癌非手术治疗中的地
位与作用[J]. 中华放射医学与防护杂志, 2010, 30(1): 102-104.
[Ma ZH, Ma YL, Feng L. The role of radiotherapy in non-surgical
treatment of primary liver cancer[J]. Zhonghua Fang She Yi Xue
Yu Fang Hu Za Zhi, 2010, 30(1): 102-104.]
[4] Park S, Yoon WS, Rim CH. Indications of external radiotherapy
for hepatocellular carcinoma from updated clinical guidelines:
Diverse global viewpoints[J]. World J Gastroenterol, 2020, 26(4):
393-403.
[5] Choi SH, Seong J. Strategic application of radiotherapy for
hepatocellular carcinoma[J]. Clin Mol Hepatol, 2018, 24(2):
114-134.
[6] Kimura SH, Ikawa M, Ito A, et al. Cyclin G1 is involved in G2/M
arrest in response to DNA damage and in growth control after
damage recovery[J]. Oncogene, 2001, 20(25): 3290-3300.
[7] 许刚, 王燕, 吴立广, 等. Cyclin G1对肝癌细胞HepG2放射敏感
度的影响及其机制[J]. 肿瘤防治研究, 2017, 44(9): 590-595. [Xu
G, Wang Y, Wu LG, et al. Effect of cyclin G1 on radiosensitivity
of hepatocellular carcinoma HepG2 cells and its mechanism[J].
Zhoong Liu Fang Zhi Yan Jiu, 2017, 44(9): 590-595.]
[8] Choi C, Koom WS, Kim TH, et al. A prospective phase 2
multicenter study for the efficacy of radiation therapy following
incomplete transarterial chemoembolization in unresectable
hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2014,
90(5): 1051-1060.
[9] Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation
therapy combined with transcatheter arterial chemoembolization
for small hepatocellular carcinoma[J]. J Gastroenterol Hepatol,
2013, 28(3): 530-536.
[10] Wahl DR, Stenmark MH, Tao Y, et al. Outcomes After
Stereotactic Body Radiotherapy or Radiofrequency Ablation for
Hepatocellular Carcinoma[J]. J Clin Oncol, 2016, 34(5): 452-459.
[11] Wei X, Jiang Y, Zhang X, et al. Neoadjuvant Three-Dimensional
Conformal Radiotherapy for Resectable Hepatocellular Carcinoma
With Portal Vein Tumor Thrombus: A Randomized, Open-Label,
Multicenter Controlled Study[J]. J Clin Oncol, 2019, 37(24):
2141-2151.
[12] Liu PH, Hsu CY, Hsia CY, et al. Prognosis of hepatocellular
carcinoma: Assessment of eleven staging systems[J]. J Hepatol,
2016, 64(3): 601-608.
[13] Wang CY, Li S. Clinical characteristics and prognosis of 2887
patients with hepatocellular carcinoma: A single center 14 years
experience from China[J]. Medicine (Baltimore), 2019, 98(4):
e14070.
[14] 田小强, 鲁世慧, 王礼学, 等. 不可手术的原发性肝癌放疗
效果影响因素及预后分析[J]. 东南大学学报(医学版), 2019,
38(6): 1029-1034. [Tian XQ, Lu SH, Wang LX, et al. Analysis of
efficiency and influence factor of intensity-modulated radiotherapy
for inoperable primary hepatocellular carcinoma[J]. Dongnan Da
Xue Xue Bao(Yi Xue Ban), 2019, 38(6): 1029-1034.]
[15] 田璐, 吴炯, 朱捷, 等. C5L2表达与肝癌患者预后分析[J]. 复旦学报
(医学版), 2017, 44(3): 280-287. [Tian L, Wu J, Zhu J, et al. Prognostic
analysis of C5L2 in patients with hepatocellular carcinoma[J]. Fu
Dan Xue Bao(Yi Xue Ban), 2017, 44(3): 280-287.]
[16] Deng Y, Zhou X, Xiang X, et al. NOR1 expr‍ession and its
relationship with prognosis in patients with hepatocellular
carcinoma[J]. J BUON, 2017, 22(5): 1186-1190.
[17] Zhao X, Chen Y, Mao Q, et al. Overexpr‍ession of YTHDF1 is
associated with poor prognosis in patients with hepatocellular
carcinoma[J]. Cancer Biomark, 2018, 21(4): 859-868.
[18] Chawla SP, Bruckner H, Morse MA, et al. A Phase Ⅰ-Ⅱ
Study Using Rexin-G Tumor-Targeted Retrovector Encoding a
Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic
Cancer[J]. Mol Ther Oncolytics, 2018, 12: 56-67.
[19] Yan J, Jiang JY, Meng XN, et al. MiR-23b targets cyclin G1 and
suppresses ovarian cancer tumorigenesis and progression[J]. J Exp
Clin Cancer Res, 2016, 35: 31.
[20] Wen W, Ding J, Sun W, et al. Cyclin G1-mediated epithelialmesenchymal
transition via phosphoinositide 3-kinase/Akt
signaling facilitates liver cancer progression[J]. Hepatology, 2012,
55(6): 1787-1798.
[21] Xu L, Lin X, Zheng Y, et al. Silencing of heat shock protein 27
increases the radiosensitivity of non?small cell lung carcinoma
cells[J]. Mol Med Rep, 2019, 20(1): 613-621.

Related articles from Frontiers Journals
[1] WU Zhuochao, HUANG Zhaohui, . Advances in Tumor-associated Macrophages in Cancer Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 870-874.
[2] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[3] HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
[4] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[5] CHEN Zegang, WANG Yongbing, OU Tao. Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 982-986.
[6] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[7] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[8] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[9] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[10] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[11] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[12] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[13] SUN Junzhao, CHENG Gang, ZHANG Jianning. Advances in Treatment of Brain Metastasis from Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 522-527.
[14] ZHAN Jianghua, WANG Zhiru, . Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
[15] ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 552-556.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed